Maxigesic IV(R) distribution deals signed in UK and Hong Kong

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 03 November 2020

Maxigesic IV
®
distribution deals signed in UK and
Hong Kong
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed exclusive Maxigesic IV
®

distribution and supply agreements for the UK and Hong Kong, with the company
targeting sales of the medicine in these territories in 2022.
The agreements cover territories with a combined population of more than 73.9m*.
The UK agreement for Maxigesic IV distribution is with the UK based global
pharmaceutical company, EDGE Pharmaceuticals and its local UK Joint Venture
partner, Kensington Pharma.
The UK market has been identified in independent research to have a number of
attractive features with 2.68m cases of surgical post-operative pain in 2020. The same
re search forecasts the post-operative pain market to grow from US$37m to $122m
between 2020 and 2028
***
.
AFT has extended its product range in Hong Kong with the addition of Maxigesic IV
®
to the existing Distribution Agreement with DKSH. After a successful launch of
Maxigesic tablets, DKSH are well positioned to continue their success with the addition
of the IV formulation once product registration in Hong Kong is complete.
AFT Pharmaceutical’s Managing Director Dr Hartley Atkinson says: “We are delighted
to further extend our distribution network in these markets. We have successfully
worked with Edge Pharmaceuticals in our local Australaisan and Asian hospital
markets since 2010 so there is already a good track record of co-operation and in
market success. Both Kensington Pharma and DKSH specialise in their respective
regions with business teams that have an excellent understanding of their local
markets.”
Maxigesic IV
®
regulatory approval in the UK is expected to conclude Q4 of 2021, with
sales then expected in the early part of 2022 while Hong Kong we expect regulatory
approval and sales in the second half of 2022.
Viv Hansen, Chairman of Edge Pharmaceutical Group says: “We are very excited to
introduce a new player into the post-operative pain management arena in the UK in
the form of Maxigesic IV®, and to further expand an existing relationship with AFT
Pharmaceuticals.”

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

Maxigesic IV
®
(Paracetamol 1000mg+ Ibuprofen 300mg solution for infusion) is an
intravenous formulation developed as a line extension to Maxigesic tablets, for use
post-operatively in hospitals when patients cannot take a medicine orally.
A major Phase 3 clinical trial conducted in the USA found that Maxigesic IV provided
significantly better pain relief than either paracetamol (acetaminophen) IV or
ibuprofen IV alone in the same doses.**
Following on from the registration of Maxigesic IV
®
in Australia and New Zealand in
mid-2019, AFT has now licensed the medication in more than 90 countries. Meanwhile,
the tablet form of Maxigesic has been licensed in more than 125 countries.
For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.


For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical business with a broad range of
products, both developed itself and in-licensed from third parties. AFT’s products
cover all major pharmaceutical distribution channels: over-the-counter, prescription
and hospital. Historically, AFT’s home markets have been Australia, New Zealand and
South-East Asia. However, the company is out-licensing its own products to licensees
and distributors to sell in an increasing number of countries around the world. The
company’s intensive Research and Development program forms the basis of its
international sales strategy. For more information about the company, visit our website
www.aftpharm.com
.
About DKSH
DKSH provides a leading range of integrated marketing expansion services across the
entire value chain, from registration to distribution. They have a capillary network
reaching more than 160,000 hospitals, clinics, pharmacies, doctors and drugstores
throughout Asia.
About Edge and Kensington
Edge Pharma Limited is focused on the supply of hospital products to a number of
countries globally, whilst Kensington Pharma Limited is focussed on the supply of
products to hospitals within the UK.

References
* 2018 population. Source: Statista, 2020

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

**Daniels, S.E, Playne, R., Stanescu, I., Zhang, J., Gottlieb, I.J, Atkinson, H.C. (2019).
Efficacy and safety of an intravenous acetaminophen/ibuprofen fixed-dose
combination after bunionectomy: A randomized, double-bli nd, factorial, placebo-
controlled trial. Clinical Therapeutics 41 (10): 1982-1995. Research sponsored by AFT
Pharmaceuticals.
*** DelveInsight Report (2020). Postoperative Pain Market Insights, Epidemiology and
Market Forecast—2028. DelveInsight